Insider Trading January 30, 2026

RENN Fund President Murray Stahl Purchases $3,084 of Fund Shares

Small insider buy executed at $2.72 per share as fund shows double-digit revenue growth and low P/E

By Avery Klein RCG
RENN Fund President Murray Stahl Purchases $3,084 of Fund Shares
RCG

Murray Stahl, President and Co-Portfolio Manager of RENN Fund, Inc. (RCG), bought $3,084 worth of the fund's common stock on January 29, 2026. The purchases were executed at $2.72 per share, marginally above the fund's prevailing trading price of $2.65. Public metrics provided show the micro-cap fund has a market capitalization of $18.59 million, 36.96% revenue growth over the past twelve months, a P/E ratio of 5.06, a financial health score labeled "GREAT," a dividend yield of 0.79%, and a current ratio of 1.6.

Key Points

  • Murray Stahl, President and Co-Portfolio Manager of RENN Fund, acquired $3,084 of common stock on January 29, 2026 at $2.72 per share.
  • RENN Fund is listed with a market capitalization of $18.59 million and reported revenue growth of 36.96% over the last twelve months.
  • Public metrics cited include a P/E ratio of 5.06, a financial health score of "GREAT," a dividend yield of 0.79%, and a current ratio of 1.6.

Summary

Murray Stahl, who serves as President and Co-Portfolio Manager at RENN Fund, Inc. (RCG), acquired shares of the fund's common stock on January 29, 2026. The total value of Stahl's purchases was $3,084, executed at a per-share price of $2.72. That purchase price is slightly higher than the fund's current quoted trading level of $2.65.


Transaction details

The total reported outlay for Stahl's transactions was $3,084. The breakdown of shares reported in connection with the purchases includes: 360 shares purchased directly by Stahl; 18 shares held by his spouse; 180 shares by Fromex Equity Corp.; 180 shares by FRMO Corp.; 296 shares by Horizon Common Inc.; 18 shares by Horizon Kinetics Hard Assets LLC; and 82 shares by Horizon Kinetics Asset Management LLC. All transactions were recorded as purchases at $2.72 per share on the stated date.


Fund metrics cited

Publicly noted metrics for RENN Fund include a market capitalization of $18.59 million and reported revenue growth of 36.96% over the last twelve months. Analysis referenced indicates the fund is trading at a P/E ratio of 5.06. Additional items highlighted are a financial health score described as "GREAT," a dividend yield of 0.79% and a current ratio of 1.6, indicating that short-term liquid assets exceed short-term liabilities.


Context and reporting notes

The information presented here draws on the fund-level metrics and the transaction detail provided for the January 29, 2026 purchases. The price per share for the purchases was $2.72, compared with a contemporaneous trading quote of $2.65. The fund is characterized as a micro-cap vehicle given the stated market capitalization figure.


What is disclosed

The facts above reflect the reported transaction amounts, the per-share execution price, the date of the trades, and the set of fund-level metrics supplied alongside the transaction record.

Risks

  • The reported purchases are small in absolute dollar terms relative to most institutional transactions; the scale of the buys may limit their effect on market liquidity for the micro-cap fund - this primarily affects micro-cap equities and asset management sectors.
  • Valuation metrics and cited financial-health indicators are summary data points and do not substitute for a full financial analysis of the fund - investors in fund shares and micro-cap equities should note this limitation.
  • Current trading price differences exist between the purchase execution price ($2.72) and the quoted trading price ($2.65), which highlights short-term price variability that can affect small-cap and micro-cap trading activity.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026